false
English
Catalog
2021 World Conference on Lung Cancer (Posters)
FP12. Pembrolizumab as a Monotherapy or in Combina ...
FP12. Pembrolizumab as a Monotherapy or in Combination With Platinum-Based Chemotherapy in NSCLC: Correlation With Blood Biomarkers
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The video presents a study on the outcomes of pembrolizumab and pembrolizumab combined with chemotherapy in treating advanced non-small cell lung cancer. The study analyzed blood-based biomarkers and identified patients who would benefit from the combined therapy. The groups were well-balanced except for age and performance status differences, but after controlling for these factors, no overall survival benefit was observed for adding chemotherapy to pembrolizumab. Certain blood biomarkers were found to be correlated with overall survival in patients treated with pembrolizumab alone, but not in patients treated with the combined therapy. A predictive score incorporating the DNLR biomarker showed that patients with high scores benefitted from the combined therapy. Treatment decisions should consider individual patient characteristics. Validation is needed.
Asset Subtitle
Liran Holtzman
Meta Tag
Speaker
Liran Holtzman
Topic
Predictive Tumor Based Assays/ Biomarkers/ Pathology
Keywords
pembrolizumab
chemotherapy
advanced non-small cell lung cancer
blood-based biomarkers
overall survival
×
Please select your language
1
English
5
普通话
11
Dutch